JPH09143082A - Protein originated from pieris papae crucivora - Google Patents

Protein originated from pieris papae crucivora

Info

Publication number
JPH09143082A
JPH09143082A JP7309528A JP30952895A JPH09143082A JP H09143082 A JPH09143082 A JP H09143082A JP 7309528 A JP7309528 A JP 7309528A JP 30952895 A JP30952895 A JP 30952895A JP H09143082 A JPH09143082 A JP H09143082A
Authority
JP
Japan
Prior art keywords
stable
cytotoxic activity
activity
tmk
pieris rapae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP7309528A
Other languages
Japanese (ja)
Inventor
Tsunetaro Koyama
恒太郎 小山
Takashi Sugimura
隆 杉村
Keiji Wakabayashi
啓二 若林
Kazumichi Koiwai
一倫 小岩井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terumo Corp
Original Assignee
Terumo Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terumo Corp filed Critical Terumo Corp
Priority to JP7309528A priority Critical patent/JPH09143082A/en
Publication of JPH09143082A publication Critical patent/JPH09143082A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide a protein originated from Pieris rapae crucivora (common white butterfly), having specific properties such as cytotoxic activity on cultured human gastric cancer cell TMK-1, etc., exhibiting strong anticancer activity at a low concentration, having low toxicity to normal cell and expected to be useful as an anticancer agent. SOLUTION: This protein originated from Pieris rapae crucivora has the following properties. (A) Molecular weight: 6.7×10<4> to 4.4×10<5> , (B) temperature stability: stable at 40 deg.C and inactivated at 60 deg.C, (C) pH stability: stable at pH3-9, (D) solubility: soluble in pure water and PBS and insoluble in chloroform and ether, (E) enzymatic stability: stable to Pronae, Proteinase-K, Nuclease P1, (Spleen) phosphodiesterase and BAP, (F) adsorbability: adsorbable to DEAE and hydroxyapatite and free from absorptivity to phosphocellulose and Affigel Blue, (G) precipitation property: forming a precipitate with an aqueous solution of ammonium sulfate of >=40% concentration and (H) cytotoxicity: exhibiting cytotoxic activity on cultured human gastric cancer cell TMK-1.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【発明の属する技術分野】本発明は、モンシロチョウ由
来の新規蛋白質に関する。詳しくは、癌細胞に対する細
胞障害活性を示すモンシロチョウ由来の新規蛋白質に関
する。
TECHNICAL FIELD The present invention relates to a novel protein derived from the cabbage butterfly. More specifically, the present invention relates to a novel protein from the cabbage butterfly that exhibits cytotoxic activity against cancer cells.

【0002】[0002]

【従来の技術】昆虫の体液に於ける有用物質の研究は、
バイオテクノロジーと関連して最近注目され、医薬品で
は、その生体防衛機構の研究からセクロピン類、アタシ
ン類デイフエンシン類の抗菌性蛋白質が発見されている
が、抗腫瘍性物質としては免疫を介して効果を示すSarc
ophagaレクチンが報告されているのみで、癌細胞に対し
直接作用する物質は発見されていない。また、抗癌剤の
研究開発は、未だその目的を充分達成されていなく、よ
り有用な抗癌剤の出現が望まれている。
2. Description of the Related Art Research on useful substances in the body fluids of insects
In recent years, attention has been paid to biotechnology in connection with biotechnology, and antibacterial proteins such as cecropins and atacins and deafensins have been discovered in the study of their biodefense mechanisms, but they are effective as antitumor substances via immunity. Show Sarc
Only ophaga lectin has been reported, and no substance that directly acts on cancer cells has been discovered. Further, research and development of anticancer agents have not yet achieved their objectives sufficiently, and the emergence of more useful anticancer agents is desired.

【0003】[0003]

【発明が解決しようとする課題】本発明は、新規な抗癌
剤を提供することを目的とする。
DISCLOSURE OF THE INVENTION An object of the present invention is to provide a novel anticancer agent.

【0004】[0004]

【課題を解決するための手段】本発明者らは、昆虫に於
ける抗癌作用をもつ物質を探索するために、ヒト胃癌培
養細胞TMK−1(以下、TMK−1という)に対する
細胞障害活性を指標として、鱗翅類体液のスクリーニン
グを行うことにより、モンシロチョウ(Pierisrapae cr
ucivora)の体液に強い細胞障害活性があることを発見
し、この知見に基づいて本発明を完成した。本発明は、
モンシロチョウ由来の因子で、幼虫、蛹または成虫の体
液に含有されており、癌細胞に対して強力な細胞障害活
性を有している。さらに、スジグロチョウ、エゾスジグ
ロチョウおよびタイワンモンシロチョウも同じ因子を含
有していることを本発明者らは確認している。
[Means for Solving the Problems] In order to search for a substance having an anticancer activity in insects, the present inventors have a cytotoxic activity against human gastric cancer cultured cells TMK-1 (hereinafter referred to as TMK-1). By screening lepidopteran body fluids using as an index, the cabbage butterfly ( Pierisrapae cr
ucivora) has a strong cytotoxic activity, and the present invention has been completed based on this finding. The present invention
This is a factor derived from the cabbage butterfly, which is contained in body fluids of larvae, pupae, or adults and has a strong cytotoxic activity against cancer cells. Furthermore, the present inventors have confirmed that the white-spotted butterfly, the black-spotted butterfly and the white-banded white butterfly also contain the same factor.

【0005】そして、この物質がTMK−1に対する細
胞障害活性を指標にして次の性質を有することを確認し
た。 (a)分子量:6.7×104〜4.4×105 (b)40℃で安定、60℃で失活 (c)pH3.0〜9.0で安定 (d)純水、PBSに溶解し、クロロホルム、エーテル
に不溶 (e)Pronase、Proteinase−K、N
uclease−P1、Phosphodiester
ase、Spleen Phosphodiester
aseまたはBAPに安定 (f)DEAEまたはHydoroxyapatite
に吸着されるが、Phosphocelluloseま
たはAffigel blueには吸着されない (g)40%以上の硫酸アンモニウム水溶液に対して沈
殿を形成する (h)赤血球、リンパ球に対して細胞障害を示さない また、投与方法は、筋注、静注等の投与方法が可能であ
るが、静注が好ましい。投与量は患者の個人差、病態等
によって異なるが、概ね成人1日あたり1.0〜50m
gである。急性毒性は、マウスに対する静注毒性LD50
値は2.2mg/kgで、既存の抗癌剤に比べて毒性が弱いこ
とが確認された。
Then, it was confirmed that this substance has the following properties using the cytotoxic activity against TMK-1 as an index. (A) Molecular weight: 6.7 × 10 4 to 4.4 × 10 5 (b) Stable at 40 ° C., deactivated at 60 ° C. (c) Stable at pH 3.0 to 9.0 (d) Pure water, PBS Dissolved in chloroform and insoluble in chloroform and ether (e) Pronase, Proteinase-K, N
sequence-P1, Phosphodiester
ase, Spleen Phosphodiester
Stable to ase or BAP (f) DEAE or Hydroxyapatite
Adsorbed by Phosphocellulose or Affigel blue (g) A precipitate is formed in 40% or more ammonium sulfate aqueous solution (h) It does not show cytotoxicity to erythrocytes and lymphocytes. Administration methods such as intramuscular injection, intramuscular injection, and intravenous injection are possible, but intravenous injection is preferable. The dose varies depending on the individual difference of the patient, the condition of the disease, etc.
g. Acute toxicity is intravenous toxicity to mice LD 50
The value was 2.2 mg / kg, which was confirmed to be less toxic than existing anticancer agents.

【0006】[0006]

【作用】詳細は不明であるが、本発明のモンシロチョウ
由来蛋白質を投与したTMK−1が細胞障害を受ける様
子を観察すると、細胞がアポトーシスを発現して細胞死
を起こすときと似ていることから、癌細胞のアポトーシ
スの発現に関与している可能性が考えられる。
[Details of action] Although details are not clear, observation of how TMK-1 to which the protein of the present invention derived from the cabbage butterfly was administered undergoes cell injury is similar to that when cells express apoptosis and cause cell death. , It may be involved in the expression of apoptosis in cancer cells.

【0007】[0007]

【実施例】【Example】

1)虫体抽出液の調製 虫体は採取後、−50℃フリーザに保存し実験に供し
た。抽出は虫体の10倍量のPBSを加え圧縮抽出し、
5000rpm15分間遠心、上清を0.22μmフイルタ
ーでろ過し不溶沈殿物を除去、これを10倍稀釈虫体サ
ンプルとして−50℃フリーザで保存し使用した。 2)虫体抽出液による細胞障害性の検出 ヒト胃癌培養細胞であるTMK−1細胞を使用し、培地
はRDF(10%FBS)を使用した。サンプルは培地で
10倍希釈系列の希釈液とし、これにトリプシン−ED
TA処理によるTMK−1細胞104/mlを接種し、37
℃、48時間培養した。細胞障害活性の判定は細胞の破
壊によるプレート剥離およびトリパンブルー染色による
生死判定を行い、ほぼ半数の細胞の死滅が観察された場
合を細胞障害活性ありとし、1000倍希釈以上に細胞
障害活性があるものを陽性と判定し、100倍希釈以下
は陰性と判定した。この方法により、各種のチョウの虫
体抽出液における細胞障害活性を検した。
1) Preparation of worm body extract After collecting the worm body, it was stored in a -50 ° C freezer and used for the experiment. Extraction was carried out by adding 10 times the amount of PBS of the worm and compression extraction,
After centrifugation at 5000 rpm for 15 minutes, the supernatant was filtered through a 0.22 μm filter to remove insoluble precipitates, which was stored as a 10-fold diluted body sample in a -50 ° C. freezer for use. 2) Detection of cytotoxicity by parasite extract TMK-1 cells, which are cultured human gastric cancer cells, were used, and the medium was RDF (10% FBS). The sample was diluted 10-fold with the culture medium, and trypsin-ED was added to this.
TMK-1 cells by TA treatment were inoculated with 10 4 / ml, 37
Culturing was performed at 48 ° C. for 48 hours. To determine the cytotoxic activity, plate detachment due to cell destruction and life-and-death determination by trypan blue staining were performed. When almost half of the cells were killed, the cytotoxic activity was determined to be 1000-fold or more. Those with a 100-fold dilution or less were determined to be negative. By this method, cytotoxic activity in various parasite extracts of butterflies was examined.

【0008】3)濃度による細胞障害性の変化 サンプルを倍数希釈で96穴プレートにTMK−1細胞
104/mlを100μl/wellとして37℃、48時間培養
後、生存細胞をKitII(XTT)法により発色し、ELISAで測
定した。 4)熱処理による細胞障害活性の変化 40℃、60℃、80℃、100℃の各ウオータバスで
エツペンドルフチューブにいれた100倍希釈サンプル
100μlを1時間加温し、2)の方法により活性を
検した。 5)pH処理による細胞障害活性の変化 pH1.0、3.0、5.0、7.0、9.0、11.0、1
4.0、の各バツフアー100μlにサンプルを100倍
希釈濃度となるようにチューブに入れ、37℃、1時間
後、2)の方法により活性を検した。 6)酵素処理による細胞障害活性の変化と化学的同定 Pronase 1mg/ml(0.01M Tris,pH7.8)、Proteinase-K 50
ug/ml(0.01M Tris,pH7.8)、Nuclease-P1 5mg/ml(10/N
buffer)、Phosphodiesterase 4U/μl(7/PDase buffe
r)、Spleen Phosphodiesterase 0.1U/μl(7/PDase buf
fer)及びBAP(10×)の各酵素に体液サンプルを加
え、体液サンプルの最終濃度を100倍希釈とし、緩く
震盪後、ウオータバスで37℃、1時間加温し、2)の
方法により活性を検した。
3) Change in cytotoxicity due to concentration After diluting the sample in 96-well plate with 10 4 / ml TMK-1 cells as 100 μl / well at 37 ° C. for 48 hours, the viable cells were subjected to the KitII (XTT) method. Was developed by and measured by ELISA. 4) Change in cytotoxic activity by heat treatment 100 μl of 100-fold diluted sample placed in an Eppendorf tube in each water bath at 40 ° C, 60 ° C, 80 ° C, 100 ° C was heated for 1 hour to activate the activity by the method of 2). I checked. 5) Changes in cytotoxic activity due to pH treatment pH 1.0, 3.0, 5.0, 7.0, 9.0, 11.0, 1
The sample was placed in a tube so that the concentration was 100 times diluted in 100 μl of each buffer of 4.0, and the activity was examined by the method of 2) after 1 hour at 37 ° C. 6) Change of cytotoxic activity by enzyme treatment and chemical identification Pronase 1 mg / ml (0.01 M Tris, pH 7.8), Proteinase-K 50
ug / ml (0.01M Tris, pH7.8), Nuclease-P1 5mg / ml (10 / N
buffer), Phosphodiesterase 4U / μl (7 / PDase buffe
r), Spleen Phosphodiesterase 0.1 U / μl (7 / PDase buf
fer) and BAP (10x), add a body fluid sample to make the final concentration of the body fluid sample 100-fold, shake gently, then heat at 37 ° C for 1 hour in a water bath to activate the activity. I checked.

【0009】7)カラムによる吸着実験 DEAE(10mM Tris.CL, pH7.5)、Phosphocellulose(10mM
HO PO4, pH7.5)、Affigel blueCM(10mM Tris.Cl, pH7.
5)、Hydroxyapatite(10mM NaPO4, pH7.0)が充填された
各処理カラム(内径1mm×長さ2cmのガラス管)内をP
BS(4ml)で洗浄し、100倍希釈サンプルを100
μl加え1時間震盪した後、遠心し、上清(表4の「上
清」)を取り除き、沈査を4mlのPBSで2回洗浄後
(表4の「洗浄液」)、溶出液(10mMTris.Cl -1M NaCl,
pH7.5)を100μl加え、1時間震盪後遠心し、上清
(表4の「溶出液」)を得、2)の方法によりそれぞれ
の活性を検した。 8)アンモニウム塩による沈殿実験 硫酸アンモニウムの飽和、80%、60%、50%、4
0%、20%、10%の各水溶液1mlにサンプルを10
0倍希釈となるように加え、5℃、24時間後、遠心沈
査を各同一濃度の硫酸アンモニウムで2回洗い、沈査を
1mlのPBSで溶解し、活性を2)の方法により検し
た。
7) Adsorption experiment by column DEAE (10mM Tris.CL, pH7.5), Phosphocellulose (10mM
HO PO 4 , pH 7.5), Affigel blue CM (10 mM Tris.Cl, pH 7.
5), P inside the processing column (1 mm inner diameter x 2 cm length glass tube) packed with Hydroxyapatite (10 mM NaPO 4 , pH 7.0)
Wash with 100 ml of BS (4 ml) and 100-fold diluted sample
After adding μl and shaking for 1 hour, centrifuge, remove the supernatant (“supernatant” in Table 4), wash the precipitate twice with 4 ml of PBS (“wash solution” in Table 4), and eluate (10 mM Tris.Cl). -1M NaCl,
100 μl of pH 7.5) was added, and the mixture was shaken for 1 hour and then centrifuged to obtain a supernatant (“eluate” in Table 4), and each activity was examined by the method of 2). 8) Precipitation experiment with ammonium salt Saturation of ammonium sulfate, 80%, 60%, 50%, 4
10 mL of the sample was added to 1 ml of 0%, 20%, or 10% aqueous solution.
The mixture was added so as to be diluted 0-fold, and after 24 hours at 5 ° C., the centrifugal precipitate was washed twice with ammonium sulfate having the same concentration, the precipitate was dissolved in 1 ml of PBS, and the activity was examined by the method of 2).

【0010】9)有機溶媒による溶出実験 クロロホルム、エーテルそれぞれ100μlに100倍
希釈サンプルを100μl、混和し、水層を除去、溶媒
を真空蒸発し、残査を100μlのPBSに溶解し、活
性を2)の方法により検した。 10)分子ろ別による分子量の測定 セントリコン3Kd、10Kd、30Kd、50Kd、100Kd
について3000rpm遠心で通過した100倍希釈サン
プル1mlに含まれているTMK−1に対する細胞障害活
性を有する物質の通過を調べるために、通過液、不通過
物質それぞれについての活性を2)の方法により検し
た。不通過物質はPBS1.0mlに溶解して測定に供し
た。 11)ゲルろ過による分子量の測定 10倍希釈サンプルをフイルター(0.22μl)で不溶物
を除き、フアルマシア社SMRART システムを使用し、カ
ラムはSUPEROSE 6PC 3.2/30を使用、溶離液は20mMリ
ン酸緩衝液(pH7.2)+0.3M NaCl、流速:40μl/mi
n、検出:UV260の条件で行い、各フラクション溶
離液について2)の方法により活性を検した。
9) Elution experiment with organic solvent 100 μl each of chloroform and ether was mixed with 100 μl of a 100-fold diluted sample, the aqueous layer was removed, the solvent was evaporated under vacuum, and the residue was dissolved in 100 μl of PBS. ). 10) Measurement of molecular weight by molecular filtration Centricon 3Kd, 10Kd, 30Kd, 50Kd, 100Kd
In order to examine the passage of a substance having a cytotoxic activity against TMK-1 contained in 1 ml of a 100-fold diluted sample passed through centrifugation at 3000 rpm, the activity of each of the passing liquid and the non-passing substance was examined by the method of 2). did. The non-passing substance was dissolved in 1.0 ml of PBS and used for the measurement. 11) Measurement of molecular weight by gel filtration 10-fold diluted sample was filtered with a filter (0.22 μl) to remove insoluble matter, and Sumarart SMRART system was used. The column was SUPEROSE 6PC 3.2 / 30 and the eluent was 20 mM phosphate buffer. (PH7.2) + 0.3M NaCl, flow rate: 40μl / mi
n, detection: UV 260 was performed, and the activity of each fraction eluate was examined by the method 2).

【0011】2. 結果 A)各種の蝶における細胞障害活性 1)、2)の方法によりアゲハチョウ、クロアゲハ、カ
ラスアゲハ、ミヤマカラス アゲハ、スミナガシ、モン
シロチョウ、オキナワシロチョウ、ツマベニチョウ、モ
ンキチョウ、キチョウ、オオムラサキ、カバタテハチョ
ウ、カイコ の13種のさなぎ及びモンシロチョウ、モ
ンキチョウ、カバタテハチョウ、ベニシジ ミチョウ、
ムラサキシジミ、カイコの6種の成虫について調べた結
果、モンシロチョウのさなぎ、成虫体液の1万倍希釈以
上に細胞障害活性が認められたが、他のものには認めら
れなかつた。 B)モンシロチョウにおける細胞障害活性 3)の方法によるモンシロチョウ体液に於ける細胞障害
活性のDose responseは図1に示す如くであり、さなぎ
(1、2)の体液の障害活性は1/1,000,000、
幼虫は1/100,000及び成虫は1/10,000でT
MK−1培養細胞に対し強い活性(>IC50)を示して
いる。 C)熱処理による細胞障害活性の変化 40℃以下では活性は保持されているが、60℃、80
℃、100℃で失活する(表1)。なお、以下の各表に
おいて−は陰性、+は陽性でほぼIC50であることを示
す。また、+の数の増加に従って細胞障害活性は上昇す
る。
2. Results A) Cytotoxic activity in various butterflies 1) By the method of 2), 13 of swallowtail butterfly, black swallowtail butterfly, crow swallowtail butterfly, lycaenoptera swallowtail butterfly, stag beetle, pierced butterfly, Okinawa butterfly, zebra butterfly, butterfly butterflies, butterfly, omurasaki, kabata butterfly, silkworm Seeds of pupae and Pieris rapae, Colias, Cabbage butterfly, Lycaenidae,
As a result of investigating 6 kinds of adults of Pleurotus cornucopiae and Bombyx mori, cytotoxic activity was observed in pupa of cabbage butterflies and adult body fluids diluted 10,000 times or more, but not in others. B) Cytotoxic activity in cabbage butterfly Dose response of cytotoxic activity in cabbage butterfly body fluid by the method of 3) is shown in Fig. 1, and the cytotoxic activity of pupa (1, 2) is 1/1000, 000,
1 / 100,000 for larvae and 1 / 10,000 for adults T
It shows a strong activity (> IC 50 ) against MK-1 cultured cells. C) Change in cytotoxic activity by heat treatment The activity is retained at 40 ° C or lower, but 60 ° C, 80
It is deactivated at 100 and 100 ° C (Table 1). In the following tables, "-" indicates negative and "+" indicates positive, which is almost IC 50 . Moreover, the cytotoxic activity increases as the number of + increases.

【0012】 (表1) 温 度 サンプル希釈率 40℃ 60℃ 80℃ 100℃ 未処理 1/1000 +++ − − − +++ 1/10000 +++ − − − +++ (Table 1) Temperature Sample dilution rate 40 ° C 60 ° C 80 ° C 100 ° C Untreated 1/1000 +++ − − − +++ 1/10000 +++ − − − +++

【0013】D)pH処理による細胞障害活性の変化 pH3.0、5.0、7.0、9.0では活性が保持されて
いるが、pH1.0以下または、11.0以上で失活する
(表2)。
D) Change in cytotoxic activity by pH treatment The activity is retained at pH 3.0, 5.0, 7.0 and 9.0, but deactivated at pH 1.0 or lower or 11.0 or higher. Yes (Table 2).

【0014】 (表2) pH サンプル希釈率 1.0 3.0 5.0 7.0 9.0 11.0 14.0 未処理 1/1000 − +++ +++ +++ +++ − − +++ 1/10000 − +++ +++ +++ +++ − − +++ (Table 2) pH sample dilution rate 1.0 3.0 5.0 7.0 9.0 11.0 14.0 untreated 1/1000 − +++ +++ +++ +++ − − +++ 1/10000 − +++ ++ + +++ +++ − − +++

【0015】E)酵素処理による細胞障害活性の変化 プロテアーゼ(Pronase, Proteinas
e−K)、ヌクレアーゼ(Nuclease−P1)、エステラー
ゼ(Phosphodiesterase, Spleen Phosphodiesterase)及
びBAPの処理では何れも活性が保持されている。プロ
テアーゼが作用しないのは活性物質に結合している脂質
等の作用阻害によるものと考えられる(表3)。
E) Change of cytotoxic activity by enzyme treatment Protease (Pronase, Proteinas)
e-K), nuclease (Nuclease-P1), esterase (Phosphodiesterase, Spleen Phosphodiesterase) and BAP all retain their activity. It is considered that the protease does not act due to the inhibition of the action of lipids and the like bound to the active substance (Table 3).

【0016】 (表3) 酵 素 サンプル希釈率 Protease Proteinase-K Nuclease-P1 Phospho BAP diesterase 1/1000 +++ +++ +++ +++ +++ 1/10000 +++ +++ +++ +++ +++ [0016] (Table 3) enzyme sample dilution rate Protease Proteinase-K Nuclease-P1 Phospho BAP diesterase 1/1000 +++ +++ +++ +++ +++ 1/10000 +++ +++ + ++ +++ +++

【0017】F)カラムによる細胞障害活性物質の吸着 DEAE及びHydroxyapatiteに吸着され、溶出液により
良く溶出されているが、Phosphocellulose及びAffigel
blueCMでは吸着されない(表4)。
F) Adsorption of cytotoxic substance by column Adsorbed on DEAE and Hydroxyapatite and well eluted by the eluent, Phosphocellulose and Affigel
It is not adsorbed by blueCM (Table 4).

【0018】 (表4)カラム DEAE Phosphocellulose AffigelBlueCM Hydroxiapatite サンプル 希釈率 1/1000 1/10000 1/1000 1/10000 1/1000 1/10000 1/1000 1/10000 未処理 +++ +++ +++ +++ +++ +++ +++ +++ 上清 − − +++ +++ +++ +++ − − 洗浄液 − − +++ +++ +++ +++ − −溶出液 +++ +++ + − + − +++ +++ (Table 4) Column DEAE Phosphocellulose AffigelBlueCM Hydroxiapatite Sample dilution rate 1/1000 1/10000 1/1000 1/10000 1/1000 1/10000 1/1000 1/10000 Untreated +++ +++ +++ +++ +++ +++ +++ +++ Supernatant − − +++ +++ +++ +++ − − Wash solution − − +++ +++ +++ +++ − − Eluate +++ +++ + - + - +++ +++

【0019】G)アムモニウム塩溶液における細胞障害
活性物質の沈殿 硫酸アンモニウムの50%以上で沈殿し、40%では一
部沈殿し、20%では沈殿しない。 H)有機溶媒による細胞障害活性因子の溶出 クロロホルム及びエーテルでの溶出は認められなかつ
た。又フェノールは細胞に対する毒性が強く判定不能で
あつた。 I)細胞障害活性物質の分子量の測定 分子ろ別セントリコンの実験ではセントリコン100K
dでの活性因子の通過が認められず、またセントリコン
100Kd以下では通過しないことから、活性物質は1
00Kdより少し大きいものと考えられた(表5)。
G) Precipitation of Cytotoxic Substances in Ammonium Salt Solution Precipitated with 50% or more of ammonium sulfate, partially precipitated with 40%, and not precipitated with 20%. H) Elution of cytotoxic factor with organic solvent No elution with chloroform or ether was observed. Further, phenol was highly toxic to cells and could not be determined. I) Measurement of the molecular weight of the cytotoxic active substance.
Since the passage of the active factor at d is not observed and it does not pass below 100 Kd of the centricon, the active substance is 1
It was considered to be slightly larger than 00 Kd (Table 5).

【0020】 (表5) サンプル セントリコン 希釈率 3Kd 10Kd 30Kd 50Kd 100Kd 通過液 1/1000 − − − − − 1/10000 − − − − − 不通過物質 1/1000 +++ +++ +++ +++ +++ 1/10000 +++ +++ +++ +++ +++ (Table 5) Sample centricon dilution ratio 3Kd 10Kd 30Kd 50Kd 100Kd Passed liquid 1/1000 − − − − − 1/10000 − − − − − Impenetrable substance 1/1000 +++ +++ +++ + ++ +++ 1/10000 +++ +++ +++ +++ +++

【0021】次にゲルろ過により細胞障害活性因子の分
子量の測定を行つた結果、フラクションの13〜14が
ピークであることからグラフ上は、1.5×10程度
の分子量と考えられる。活性は6.7×10〜4.4
×10の部分にある。リテンションタイムにより算出
すると、1.5×10程度と考えられる。
Next, the molecular weight of the cytotoxic activator was measured by gel filtration. As a result, the fractions 13 to 14 had peaks, and it is considered that the molecular weight is about 1.5 × 10 5 on the graph. The activity is 6.7 × 10 4 to 4.4.
It is in the portion of × 10 5 . When calculated from the retention time, it is considered to be about 1.5 × 10 5 .

【0022】[0022]

【発明の効果】本発明のモンシロチョウ由来蛋白質は低
濃度で強い抗癌活性を示す。また、健常細胞に対する毒
性が低いので、抗癌剤としての利用が期待される。
INDUSTRIAL APPLICABILITY The protein derived from the cabbage butterfly of the present invention exhibits strong anticancer activity at a low concentration. Further, since it has low toxicity to healthy cells, it is expected to be used as an anticancer agent.

【図面の簡単な説明】[Brief description of the drawings]

【図1】 ELISAによる生存細胞の測定Figure 1: Measurement of viable cells by ELISA

───────────────────────────────────────────────────── フロントページの続き (72)発明者 若林 啓二 東京都目黒区東が丘2−5−28 (72)発明者 小岩井 一倫 神奈川県足柄上郡中井町井ノ口1500番地 テルモ株式会社内 ─────────────────────────────────────────────────── ─── Continuation of front page (72) Keiji Wakabayashi 2-5-28 Higashigaoka, Meguro-ku, Tokyo (72) Inventor Kazunori Koiwai 1500 Inoguchi, Nakai-cho, Ashigarakami-gun, Kanagawa Terumo Corporation

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】次の(a)〜(h)の性質を有するモンシ
ロチョウ(Pieris rapae crucivora)由来蛋白質 (a)分子量:6.7×104〜4.4×105 (b)40℃で安定、60℃で失活 (c)pH3.0〜9.0で安定 (d)純水、PBSに溶解し、クロロホルム、エーテル
に不溶 (e)Pronase、Proteinase−K、N
uclease−P1、Phosphodiester
ase、Spleen Phosphodiester
aseまたはBAPに安定 (f)DEAEまたはHydoroxyapatite
に吸着されるが、Phosphocelluloseま
たはAffigel blueには吸着されない (g)40%以上の硫酸アンモニウム水溶液に対して沈
殿を形成する (h)ヒト胃癌培養細胞TMK−1に対し細胞障害活性
を示す
1. A protein derived from the Pieris rapae crucivora derived from the Pieris rapae crucivora having the following properties (a) to (h): (a) molecular weight: 6.7 × 10 4 to 4.4 × 10 5 (b) at 40 ° C. Stable, deactivated at 60 ° C (c) Stable at pH 3.0 to 9.0 (d) Soluble in pure water and PBS, insoluble in chloroform and ether (e) Pronase, Proteinase-K, N
sequence-P1, Phosphodiester
ase, Spleen Phosphodiester
Stable to ase or BAP (f) DEAE or Hydroxyapatite
Adsorbed on Phosphocellulose or Affigel blue (g) A precipitate is formed in 40% or more ammonium sulfate aqueous solution (h) Cytotoxic activity against human gastric cancer cell line TMK-1
JP7309528A 1995-11-28 1995-11-28 Protein originated from pieris papae crucivora Pending JPH09143082A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP7309528A JPH09143082A (en) 1995-11-28 1995-11-28 Protein originated from pieris papae crucivora

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7309528A JPH09143082A (en) 1995-11-28 1995-11-28 Protein originated from pieris papae crucivora

Publications (1)

Publication Number Publication Date
JPH09143082A true JPH09143082A (en) 1997-06-03

Family

ID=17994104

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7309528A Pending JPH09143082A (en) 1995-11-28 1995-11-28 Protein originated from pieris papae crucivora

Country Status (1)

Country Link
JP (1) JPH09143082A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001025390A (en) * 1999-07-15 2001-01-30 Meiji Milk Prod Co Ltd Gene coding for apoptosis-inducing protein
JP2016053003A (en) * 2014-09-03 2016-04-14 学校法人 東洋大学 Polypeptide derived from coccoidea

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001025390A (en) * 1999-07-15 2001-01-30 Meiji Milk Prod Co Ltd Gene coding for apoptosis-inducing protein
JP2016053003A (en) * 2014-09-03 2016-04-14 学校法人 東洋大学 Polypeptide derived from coccoidea

Similar Documents

Publication Publication Date Title
Vogel Cobra venom factor: the complement-activating protein of cobra venom
US6803454B2 (en) Method for extraction and purification of cartilage type proteoglycan
JPH02503202A (en) Membrane calcium channels and factors and methods for blocking, isolating and purifying calcium channels
de Melo et al. HGA-2, a novel galactoside-binding lectin from the sea cucumber Holothuria grisea binds to bacterial cells
Sitohy et al. Preliminary assessment of potential toxicity of methylated soybean protein and methylated β-lactoglobulin in male Wistar rats
Harm et al. Blood compatibility—an important but often forgotten aspect of the characterization of antimicrobial peptides for clinical application
Hamed et al. Antimicrobial activities of lectins extracted from some cultivars of Phaseolus vulgaris seeds
Lischer et al. Anti-breast cancer activity on MCF-7 cells of melittin from Indonesia’s Apis cerana: An in vitro study
Marinovic et al. Crotamine: Function diversity and potential applications
JPH09143082A (en) Protein originated from pieris papae crucivora
James et al. In vivo and in vitro neutralizing potential of Rauwolfia serpentina plant extract against Daboia russelli Venom
US4012502A (en) Snake venom inhibitor material and method of purification
Chen et al. Purification and characterization of an antimicrobial protein from Gastrodia elata Blume tubers
JP2007308614A (en) Cell death inhibitor or the like of nerve cell
JP6512681B2 (en) Polypeptide from a scale insect
JPS63164895A (en) Lectin-like protein originated from cultured cell, its production and antitumor agent composed mainly of said substance
JPS59141519A (en) Protein having carcinostatic action
JP3711356B2 (en) Kurokawa-derived lectin and its isolation and purification method
US9260536B2 (en) Capture of pathogenic and non-pathogenic biopolymers and bioparticles
JP4810638B2 (en) Antibacterial oligosaccharide and method for producing the same
JP2617704B2 (en) Antitumor agent
WO1984003104A1 (en) Dna synthesis-repressing substance
CN117343131A (en) Snake venom polypeptide and application thereof
Whaler VI. NEUROTOXINS
KR100250714B1 (en) Therapeutic agent for treating infections of pseudomonas aeruginosa